22 min listen
AACR Virtual Spectacular: Dr Leora Horn Comments on the New COVID-19 Lung Cancer Registry
AACR Virtual Spectacular: Dr Leora Horn Comments on the New COVID-19 Lung Cancer Registry
ratings:
Length:
13 minutes
Released:
Apr 29, 2020
Format:
Podcast episode
Description
Dr Leora Horn of Vanderbilt University Medical Center discusses outcomes for patients with lung cancer and COVID-19 as well as the human implications of social distancing.
Additional Resources
* AACR Virtual Annual Meeting I: April 27-28, 2020. (https://aacr20.onlineeventpro.freeman.com/)
* COVID-19 and Cancer. AACR 2020. Session (https://aacr20.onlineeventpro.freeman.com/live-stream/15335630/COVID-19-and-Cancer)
* Garassino, MC. TERAVOLT (Thoracic cancERs international coVid 19 cOLlaboraTion): First results of a global collaboration to address the impact of COVID-19 in patients with thoracic malignancies. AACR 2020. Abstract (https://www.abstractsonline.com/pp8/#!/9045/presentation/10927)
* Minello A. The pandemic and the female academic. Nature 2020;[Online ahead of print]. Abstract (https://www.ncbi.nlm.nih.gov/pubmed/32303729)
Additional Resources
* AACR Virtual Annual Meeting I: April 27-28, 2020. (https://aacr20.onlineeventpro.freeman.com/)
* COVID-19 and Cancer. AACR 2020. Session (https://aacr20.onlineeventpro.freeman.com/live-stream/15335630/COVID-19-and-Cancer)
* Garassino, MC. TERAVOLT (Thoracic cancERs international coVid 19 cOLlaboraTion): First results of a global collaboration to address the impact of COVID-19 in patients with thoracic malignancies. AACR 2020. Abstract (https://www.abstractsonline.com/pp8/#!/9045/presentation/10927)
* Minello A. The pandemic and the female academic. Nature 2020;[Online ahead of print]. Abstract (https://www.ncbi.nlm.nih.gov/pubmed/32303729)
Released:
Apr 29, 2020
Format:
Podcast episode
Titles in the series (100)
Dr Tom Lynch on Adjuvant EGFR TKIs in Lung Cancer and COVID-19 in Seattle: Dr Tom Lynch comments on the current status of oncology research and data soon to be presented from a Phase III trial evaluating the EGFR TKI osimertinib as adjuvant therapy for patients with non-small cell lung cancer and EGFR tumor mutations. by Oncology Today with Dr Neil Love